The collaboration will offer third parties with a unified solution for vaccine conjugation, manufacturing, and supply. Credit: Ground Picture / Shutterstock.com.

Contract development and manufacturing organisation (CDMO) Intravacc and biotechnology company Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.

This collaboration is set to provide third parties with a comprehensive solution for vaccine conjugation, manufacturing, and supply, streamlining the process for developers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Intravacc will provide its extensive technical capabilities, advanced facilities, and expertise in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines.

This expertise is crucial in ensuring the quality and efficacy of vaccines as they progress from concept to commercialisation.

Intravacc CEO Dr Jan Groen said: “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionise the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”

See Also:

Primrose Bio will complement Intravacc’s offerings with its ultra-pure manufacturing, supply chain, and regulatory support for the PeliCRM197 carrier protein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As a key component in conjugate vaccine formulations, PeliCRM197 is the only commercial CRM197 used in licenced vaccines and is available for purchase.

This carrier protein can be supplied in various quantities and grades, ranging from milligrams to kilograms, catering to both research and GMP applications.

The latest collaboration between the parties represents a strategic alignment with the potential to significantly advance vaccine development.

Primrose Bio CEO Dr Helge Zieler said: “Expanding the capability of our PeliCRM197 franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development.

“With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”

In October 2022, Intravacc received a contract worth $14.6m from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG).